

EXTERNALLY-LED PATIENT-FOCUSED DRUG DEVELOPMENT MEETING
ON STXBP1-RELATED DISORDERS: AGENDA

October 20, 2023
10:00am-3pm ET

- 10:00 am- 10:05 am Welcome**
- Charlene Son Rigby, President and Co-founder, STXBP1 Foundation
- 10:05 am-10:15 am FDA Opening Remarks**
- Michelle Campbell, PhD, Associate Director for Stakeholder Engagement and Clinical Outcomes, Office of Neuroscience, CDER, FDA
- 10:15 am-10:30 am STXBP1 Clinical Overview**
- Ingo Helbig, MD, Division of Neurology and the Director of Genomic Science at Children's Hospital of Philadelphia
- 10:30 am-10:35 am Introduction and Meeting Overview**
- James Valentine, JD, MHS, Meeting Moderator
- 10:35 am-10:45 am Demographic Polling**

Session 1 – Living with STXBP1 Symptoms and Daily Impact

- 10:45 am-11:10 am Patient/Caregiver Panel 1**
- 5 patient/caregiver panelists
- 11:10 am -12:30 pm Audience polling & moderated discussion**
- Live audience discussion with patients/caregivers, including polling, telephone call-ins, and written comments
- 12:30pm- 1:00 pm Lunch Break**

Session 2 – Current and Future Treatments for STXBP1

1:00 pm-1:25 pm

Patient/Caregiver Panel 2

- 5 patient/caregiver panelists

1:25 pm-2:40 pm

Audience polling & moderated discussion

- Live audience discussion with patients/caregivers, including polling, telephone call-ins, and written comments

2:40 pm-2:50 pm

Summary Remarks

- Larry Bauer, RN, MA

2:50 pm- 3:00 pm

Closing Remarks

- Charlene Son Rigby, President and Co-founder, STXBP1 Foundation

Adjourn